Background Pemphigus vulgaris (PV) is a rare autoimmune bullous disease, which can present with recalcitrant oral mucosal lesions. Optimal management of PV relies upon careful clinical assessment and documentation. Objectives The primary aim of this study was to validate the Oral Disease Severity Score (ODSS) for the assessment of oral involvement in PV. A secondary aim was to compare its inter-and intraobserver variability and ease of use with the Physician's Global Assessment (PGA) and the oral scoring methods used in the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and the Pemphigus Disease Area Index (PDAI). Methods Fifteen patients with mild-to-moderately severe oral PV were scored for disease severity by 10 oral medicine clinicians using the ODSS, the PGA and the oral sections of ABSIS and PDAI. Two clinicians rescored all patients after a minimum 2-h interval. Results Interobserver reliability was assessed using an intraclass correlation coefficient (ICC). For the ODSS total score the ICC was 0Á83, for PDAI (oral total activity) 0Á79, ABSIS (oral total) 0Á71 and PGA 0Á7. Intraobserver agreement between initial scoring and rescoring of the same patient by two clinicians demonstrated an ICC for each of 0Á97 and 0Á96 for ODSS total score; 0Á99 and 0Á82 for PDAI oral activity; 0Á86 and 0Á45 for ABSIS total; and 0Á99 and 0Á64 for PGA. Convergent validity was good, with a correlation coefficient > 0Á5 (P < 0Á001). The mean AE SD times taken to complete each scoring method were ODSS 76 AE 37 s, PDAI 117 AE 16 s and ABSIS 75 AE 19 s. Conclusions This study has validated the ODSS for the assessment of oral PV. It has shown superior inter-and intraobserver reliability to PDAI, ABSIS and PGA and is quick to perform.
What does this study add?
• The ODSS is shown to be a thorough and sensitive, yet quick assessment tool for oral involvement in PV.
• Its versatility for use additionally in MMP and LP is an added advantage over previously validated methods.
What are the clinical implications of this work?
• We propose that the ODSS would be a useful supplement for future multicentre studies, as well as for recording sequential disease activity in the clinic.
Pemphigus vulgaris (PV) is a rare autoimmune bullous disease, which can present with or develop into a condition with severe and recalcitrant oral mucosal lesions. 1 Optimal management of such cases relies upon careful clinical assessment and documentation, without which there may be a delay in the recognition of therapeutic response or of treatment failure.
To determine the optimal management for PV, numerous clinical trials have been undertaken. However, assessment of efficacy has been hampered by the lack of validated clinical outcome measures, particularly where mucosal sites have been affected. A Cochrane review revealed that over 116 outcome measures have been described in 96 articles and concluded that there was insufficient evidence to determine which therapy is optimal. 2 Since that time there have been further systematic reviews, which similarly have been unable to establish clearly the optimal therapeutic guidelines. 1, 3 Several PV disease activity indices including the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) have been validated. [4] [5] [6] While these methodologies include mucosal scores, our aim was to compare their sensitivity with a more detailed methodology for scoring oral mucosal sites. Given the recalcitrant nature of oral lesions in severe PV it is imperative that a formally validated, sensitive and user-friendly scoring methodology for the oral mucosa be available to facilitate international collaboration and multicentre studies, as well as providing more useful comparison of clinical outcomes in smaller case series. Thereafter, sequential scores over time relating disease activity with other outcome measures, including quality-of-life measures and desmoglein antibody titres, will be most informative.
The Oral Disease Severity Score (ODSS) is a comprehensive scoring methodology devised by the oral medicine group at Guy's Hospital as part of a strategy of having disease severity scores applicable to most, if not all, oral mucosal diseases. It was first developed from a scoring system devised for multisite mucous membrane pemphigoid (MMP). 7 The ODSS records the presence of lesions and degree of activity at multiple oral sites. Additionally, it includes a subjective assessment of the patient's degree of oral pain over the preceding week.
Previous studies have demonstrated that the ODSS has good inter-and intraobserver reliability in both lichen planus (LP) and MMP. 8, 9 In addition it has been shown to be valuable in the assessment of therapeutic response over time in severe mucosal LP and PV. 10, 11 The primary aim of this study was to validate the ODSS for the assessment of oral involvement in PV. We invited oral medicine clinicians from four centres in the U.K. with a range of experience in scoring methodologies and included patients with a range of disease severity of oral pemphigus. In the validation of the ODSS we investigated the inter-and intraobserver variability and ease of use. The ODSS was used in parallel with the PGA and the oral part of two recently proposed and validated systems for autoimmune bullous diseases: ABSIS and the PDAI. We additionally sought to assess convergent validity between PDAI and the ODSS, ABSIS and PGA. [4] [5] [6] 12 Patients and methods
Research ethics approval was obtained (REC15/ES/0038). The study was performed within the Oral Medicine Department at Guy's Hospital, London. Ten oral medicine clinicians from four U.K. oral medicine centres were involved. Fifteen patients were scored using the ODSS in addition to the oral sections of the ABSIS, PDAI and PGA. Patients were scored during the course of 1 day. Each patient remained in one room with an assistant who recorded the scores and timed each methodology. The clinicians rotated until all patients had been scored. Two clinicians rescored all patients after a minimum 2-h interval in order to reduce recall (see statistical methods below). Twelve sets of scores were recorded for each patient.
Physicians
Clinicians participating in the study were either consultants in oral medicine (n = 8) or oral medicine trainees (n = 2). Six clinicians were both medically and dentally qualified, with one additionally a practising dermatologist, while the remaining four clinicians were dentally qualified alone. Five clinicians routinely used the ODSS in clinical practice, while the remaining five did not. PDAI and ABSIS were not routinely used by any of the clinicians. Prior to the study day, a set of training clinical slides demonstrating the ODSS system, ABSIS and PDAI was circulated to all the clinicians. On the study day, the clinicians met with the chief investigator for a detailed discussion of each methodology and a review of the clinical slide set, and to familiarize themselves with the calibration of each system. All clinicians examined all of the patients once, and two clinicians examined all of the patients twice (with a 2-h interval to reduce recall).
Patients
Fifteen adult patients (aged 18-80 years) with a confirmed diagnosis of predominantly oral mucosal PV (based on clinical findings, histopathology and positive direct immunofluorescence, as previously described) 13 participated in the study.
Patients were recruited consecutively from the oral medicine department. The visit replaced one of their routine follow-up appointments. Thirteen had mild-to-moderately severe oral disease, one was in clinical remission and one had severe oral disease. All were on systemic treatment (nine mycophenolate mofetil, four azathioprine and two rituximab with and without prednisolone) at the time of the study.
Oral Disease Severity Score
The ODSS is a comprehensive oral scoring system previously validated for LP ( Fig. 1) [Correction added on 20 July 2018, after first online publication: the new figure 1 was updated]. 8 It has additionally been used sequentially in PV and LP. 10, 11 It divides the mouth into 17 sites weighted according to the area of possible involvement, with each allocated a site score of 0-2. The sites include the outer/inner lips, left and right buccal mucosa, six gingival segments, hard palate (left/right or both), soft palate (left/right or both), dorsum tongue (left/ right or both), left ventral tongue, right ventral tongue, floor of mouth (left/right or both) and oropharynx. Individual sites (or units of a site) are then allocated an activity score (0-3), reflecting mild inflammation (minimal erythema or a white 'healing' mucosa) = 1 (Fig. 2a) ; moderate inflammation (marked erythema but no ulceration) = 2 ( Fig. 2b ) and ulceration = 3 ( Fig. 2c ). Additionally, a subjective assessment of the patient's oral pain in the preceding week is included (verbal rating scale of 0-10). The theoretical maximum total score is 106; however, > 95% of patients would be expected to have scores in the range from 0 to 60, representing a clinical range from remission to severe disease.
Autoimmune Bullous Skin Disorder Intensity Score
The ABSIS is designed to assess the extent and quality of skin and oral lesions (Fig. 3 ). It has a total score of 206 (150 points for skin involvement, 11 for oral and 45 for subjective discomfort). For the present study we used only the oral mucosal part of the system. This evaluates 11 distinct anatomical sites. The presence or absence of any lesion (blister/erosion) is allocated a score of 0 or 1, with a total score of 11. The second part of the score is for severity of symptoms, which details the discomfort while eating and drinking, with a maximum score of 45. A higher score represents more severe disease. 4 Pemphigus Disease Area Index
The PDAI was developed by the International Pemphigus Committee to capture the spectrum of PV (Fig. 4) . 5, 6 The skin, scalp and mucosa are scored separately for both the number of lesions (ulcers or erosions) present and evidence of damage (skin and scalp). There is no score for erythema/damage in the oral mucosa. The total possible score is 250 (120 for skin, 10 for scalp and 120 for mucosal activity). 5 For the purpose of this study only oral mucosal surfaces were scored, with a possible total of 90 (excluding the eyes, nose and anogenital areas).
Physician's Global Assessment
The PGA is a simple scoring method for inflammatory skin disease (Fig. 5 ). It is a 10-point analogue scale from 0 (perfect health) to 10 (worst condition imaginable). The clinicians score the participants on a global impression of their disease. This score method has been validated in a number of diseases including psoriasis and eczema. 6, 12, 14 Time for scoring methodology completion
An independent assistant scored the time (in seconds) taken by each clinician to obtain a disease severity score for each method using a stopwatch.
Statistical methods
Interobserver reliability was undertaken with 10 observers (clinicians) scoring all patients with each of the four scoring methodologies. A sample size of 15 patients was required to achieve an intraclass correlation coefficient (ICC) of 0Á77 for the interobserver reliability. Intraobserver reliability was tested with two replications per patient (as per test-retest) with a minimum of 2 h between scores to minimize the risk of recall. As the involvement was more onerous (burden, time or money resources etc.) for the rater than for the patient, taking the rater as fixed in the factorial design was more efficient. We fixed the number of raters to two and found the sample size required in terms of the number of patients (who are assumed to be a random sample from the patient population). With both raters performing two replications in each methodology in all the patients, a total of 15 patients provides 80% power to detect an ICC difference of 0Á50 (relative to a null value of 0Á20). Anticipating an ICC of 0Á85, 15 patients with two replications will yield a width of 0Á30 in the 95% confidence interval (CI).
Multilevel models were used to quantify the intra-and interobserver reliabilities of the continuous measures. Assessment for the level of agreement in terms of the ICCs for ordinal or continuous measures followed well-established benchmark limits (Fleiss and Altman's benchmark scales). 15, 16 Landis-Koch benchmark values were followed when kappa coefficients were used for categorical outcomes. In all cases, for more rigour, in addition to the point estimate, we took into account the lower bound of the 95% CI. 17 Convergent validity was calculated using the Spearman rank correlation coefficient.
Results
Fifteen patients (11 female, four male) with confirmed PV were included. Their mean AE SD age was 56 AE 14Á2 years (range 23-77).
Distribution of scores
The mean total ODSS score was 22Á3 AE 12Á8 (range 0-68); median 22, interquartile range (IQR) 12Á75-29; reflecting mild-to-moderately severe disease in 13 of the 15 patients. In one patient no lesions were identified (score 0), while another with very severe disease had a score of 68. The mean PDAI activity score for oral mucosa was 14Á6 AE 7Á7 (range 0-42); median 13 (IQR 11Á0-16Á5).
For ABSIS, the mean total score was 12Á5 AE 1Á1 (range 0-43); median 11Á7 (IQR 5Á4-17Á5). The mean score for oral involvement was 3Á6 AE 2Á3; median 4 (IQR 2-5). For disease severity the mean was 8Á4 AE 7Á0; median 8 (IQR 0Á5-12Á5).
The mean PGA score was 6Á1 AE 0Á9 (range 0-9); median 3 (IQR 1-8).
Reliability

Test-retest reliability
Intraobserver agreement between initial scoring and rescoring of the same patients demonstrated an ICC for each of the two examiners of 0Á97 and 0Á96 for ODSS total, 0Á95 and 0Á97 for ODSS site, 0Á98 and 0Á95 for ODSS activity and 0Á97 and 0Á90 for ODSS pain ( Table 1) . As only oral mucosal sites were scored for the PDAI, the total PDAI reflects activity only with no damage score. The PDAI ICCs were 0Á99 and 0Á82. The ABSIS total ICCs were 0Á86 and 0Á45, with ABSIS involvement 0Á94 and 0Á90 and ABSIS severity 0Á91 and 0Á44. The ICCs for PGA were 0Á99 and 0Á64.
Interobserver reliability
The ICC (95% CI) for the total ODSS score was 0Á83 (0Á71-0Á94), ODSS site 0Á69 (0Á52-0Á86), ODSS activity 0Á83 (0Á72-0Á94) and ODSS pain 0Á90 (0Á84-0Á97) ( Table 2 ). The PDAI activity ICC was 0Á79 (0Á65-0Á92). For ABSIS, the ICC for total score was 0Á71 (0Á55-0Á88), with oral involvement 0Á72 (0Á57-0Á83) and severity 0Á67 (0Á50-0Á85). The PGA ICC was 0Á70 (0Á54-0Á87).
Convergent validity
The convergent validity scores between the PDAI activity (gold standard) and the other indices are detailed in Table 3 . There was good convergent validity for all indices (ODSS total 0Á70, ABSIS total 0Á51 and PGA 0Á77; all P < 0Á001).
Time taken for completion of disease scoring methodologies
The mean time to obtain a disease severity score for ODSS was 76 AE 37 s, for PDAI 117 AE 16 s and ABSIS 75 AE 19 s.
Discussion
This study has shown that the ODSS is a valid method for assessment of disease severity for oral PV and has higher inter- and intraobserver reliability than the previously validated methodologies PDAI, ABSIS and PGA.
The patient sample used in this study reflects the reported sex and age distribution of PV, with a broad range of oral disease severity (mild to severe) despite all patients being on systemic treatment. 18 The mean and range of the scores for ABSIS and PDAI were detailed by Rosenbach et al. in their validation study and reflect a similar and potentially milder group of patients. 6 In terms of the reliability of the methodologies, the intraobserver scores were excellent, almost perfect (ICC > 0Á9), for all parameters for ODSS total score (0Á96-0Á97), PDAI (0Á82-0Á99) and ABSIS total score (0Á45-0Á86). Intraobserver scores were given a benchmark value of good/substantial for PDAI activity and fair/moderate for total score for ABSIS. For PGA, the benchmark value was good/substantial. The data of Rosenbach et al. showed that for intraobserver reliability, using the test-retest method (two replications), the ICC was 0Á98 (95% CI 0Á97-1Á0) for PDAI mucous membrane activity and 0Á99 (95% CI 0Á97-1Á0) for ABSIS oral involvement. ABSIS subjective discomfort was not calculable due to a lack of variability among the patients. Our data have shown better intraobserver scores for ODSS than the other methods examined.
For interobserver reliabilities, the ODSS total score had an ICC of 0Á83. Benchmarking values were very good or excellent 
ABSIS, Autoimmune Bullous Skin Disorder Intensity Score; PDAI, Pemphigus Disease Area Index; PGA, Physician's Global Assessment; IQR, interquartile range; ICC, intraclass correlation coefficient; CI, confidence interval.
a Assessment for the level of agreement in terms of the ICCs followed Fleiss and Altman's benchmark scales. 15, 16 for total score, activity and pain. For PDAI activity, the ICC was 0Á79 (very good), for ABSIS total score the ICC was 0Á71 (good/substantial) and for PGA it was 0Á7 (good/substantial). Rosenbach et al. reported an ICC of 0Á84 for PDAI, 0Á85 for extent of mucosal disease with ABSIS, and 0Á89 for subjective involvement. In our study, the ODSS was more reliable among the scoring clinicians than the three other methods. The average time taken for clinicians to complete each of the scoring tools was < 2 min; the longest completion time was for PDAI. The time difference for completion of both the PDAI and ABSIS may in part be due to a lack of familiarity with the scoring systems, as the clinicians did not routinely use either system; nevertheless, the total time for each of the three was considered acceptable in a routine clinic. Furthermore, there was no significant difference in the mean time taken by clinicians scoring the ODSS clinically for the first time compared with those familiar with the system, thus lack of familiarity should not have significantly influenced these data.
In terms of convergent validity using PDAI as the previous 'gold standard', ODSS total score demonstrated good correlation with the PDAI activity score (correlation coefficient 0Á7, P < 0Á001).
There are some limitations to this study. Firstly, a valid outcome measure for PV should ideally be reliable, discriminatory, sensitive, accurate, feasible and close to a gold standard, and have excellent external validity. 19, 20 Potentially, scores at the lower end of the spectrum for all methodologies might reduce the sensitivity and reproducibility of each scoring system. However, the fact that ODSS details more oral sites than either ABSIS or PDAI, has a higher maximum score and combines both a semiquantitative score (site) and a qualitative score (activity) permits detailed differentiation between patients. Ideally the cohort would have included untreated patients with severe disease, but this would have necessitated withholding treatment. Secondly, the scoring instruments compared here looked only at the oral mucosal lesions and therefore would need to be undertaken alongside a skin and other mucosal-site score. Thirdly, intraobserver reliability was tested with a minimum 2-h interval. This interval may allow recall bias, and ideally this would be longer, but more than a day or two might be associated with changes in disease activity. Furthermore, patients would need to reattend, which adds an impractical level of complexity to the study.
In terms of external validity, the sample of patients included would ideally be randomly selected from a large cohort. Our sample was selected consecutively from patients under current follow-up, with predominantly active disease and who were able to attend on the study day. We did not exclude any patient over and above those constraints. Clinicians with an interest in the field of immunobullous disease were invited and again were not randomly selected. The intraobserver reliability may have been improved by increasing the replications including those familiar and unfamiliar with the scoring methodologies. However, using clinicians who are experienced in scoring methodologies is likely to have had a positive effect on all indices. Furthermore, this provided more data as there were a further 30 scores to analyse than just a further 10 if each observer had rescored only one patient. Finally, sequential use of ODSS in case reports and a small case series has demonstrated the efficacy of treatment in recalcitrant PV and LP. It now needs to be tested sequentially alongside PDAI and ABSIS to demonstrate sensitivity to change in disease activity and response to treatment in this cohort. 10, 11, 21 We asked clinicians to comment on their experiences of each method. They all reported the ODSS to be the easiest method to use and felt that it more accurately and objectively recorded the extent of oral disease in PV. All would consider incorporating it into their routine assessment. The PDAI was considered to have potential for variable interpretation of the clinical features. The necessity of a lesion to be defined as a blister or an erosion precluded those lesions that were almost healed. It was also difficult to know how to score the number of lesions if confluent on the gingiva and including a few teeth amounting to < 2 cm, or if patchy and multiple. The ABSIS score was much easier to use to reflect severity, although it also required lesions to be blisters or erosions, thereby losing some sensitivity in white or healing areas. It had a substantial subjective component requiring the patient to report symptoms with foods, and the replies sometimes depended on how the questions were put to the patient. The system seemed weighted too strongly on this subjective component, which was not felt to allow for accurate recording of clinical severity. Finally the PGA, while simple, was felt to offer little information regarding the objective oral involvement of PV and potentially would be less valuable for sequential monitoring of disease.
The ODSS has been used in a sequential study of 23 patients and demonstrated a positive association between oral disease activity and salivary antibodies to desmoglein (Dsg)3.
21 ODSS has also previously been used to demonstrate cumulative efficacy with rituximab in patient with recalcitrant oral pemphigus where serial serum IgG Dsg3 titres followed clinical scores over several years of follow-up. 11 In a cross-sectional study of patients with PV comparing the inter-rater validity of PDAI, the Pemphigus Vulgaris Activity Score and ABSIS, together with convergent validity according to anti-Dsg values, both inter-rater reliability and convergent validity were highest with PDAI. 22 In analysis of sequential serum samples from patients with PV, the anti-Dsg3 indices showed a correlation with PDAI scores, 23 while in a further study no correlation was found with either PDAI or ABSIS. 24 Among patients with predominantly mucosal PV, there was no correlation between either serum or salivary anti-Dsg1 or anti-Dsg3 antibodies and the total objective component of ABSIS; however, serum antiDsg1 antibodies did correlate with cutaneous ABSIS. 25 As PV is a rare disease, establishing optimal therapeutic regimens has been very difficult. Multicentre collaborative trials are therefore essential. 20 However, the lack of a universally accepted outcome measure has been highlighted in a recent systematic review. 1 The PDAI is considered to be the optimal method for multisite disease in use to date. While patients with PV may initially have both mucosal and cutaneous lesions, many are left with pure oral disease, which is often severe and debilitating. We propose that a more sensitive method of assessing oral PV needs to be in place for these cases. The ODSS was first developed and published for use in LP, and its use was extended as part of a strategy of developing disease severity scores for a number of oral mucosal diseases. 8, [26] [27] [28] It incorporates objective measures of disease activity and severity, as well as including subjective patient data, allowing for a comprehensive appraisal of mucosal disease. 8 The ODSS has been used in our department for more than 10 years and has been externally evaluated for use in MMP; it has also shown efficacy of treatment for PV and LP. [9] [10] [11] In this study, the ODSS has been shown to be a reliable and reproducible tool for recording oral PV disease activity, with inter-and intrarater reliability at least as good as with PDAI for oral lesions. It is simple to use and facilitates detailed recording of both the site and the severity of lesions, including those that are healing. We propose that this scoring tool would be a useful supplement for future multicentre studies, as well as recording sequential disease activity in the clinic. We are currently evaluating data on sequential scores using all four methods over a 1-year follow-up to clarify which is the most sensitive to subtle changes in disease activity.
